{"id":961885,"date":"2026-05-12T19:03:10","date_gmt":"2026-05-12T23:03:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/"},"modified":"2026-05-12T19:03:10","modified_gmt":"2026-05-12T23:03:10","slug":"anteris-announces-results-for-the-first-quarter-of-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/","title":{"rendered":"Anteris Announces Results for the First Quarter of 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MINNEAPOLIS and BRISBANE, Australia, May  12, 2026  (GLOBE NEWSWIRE) &#8212; <strong>Anteris Technologies Global Corp.<\/strong> (\u201cAnteris\u201d or the \u201cCompany\u201d) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.<\/p>\n<p align=\"justify\">\n        <strong>Q1 2026 Highlights<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:10pt;text-align:justify\">Completed aggregate capital raises totalling $320 million in January 2026 to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR<sup>\u00ae<\/sup> THV System<\/li>\n<li style=\"margin-top:5pt;margin-bottom:10pt;text-align:justify\">Advanced PARADIGM Trial recruitment, supported by ongoing regulatory and operational work to activate additional countries and sites \u2013 post quarter-end, U.S. enrollment commenced<\/li>\n<li style=\"margin-top:5pt;margin-bottom:10pt;text-align:justify\">Presented clinical data from the ongoing EMBARK Study and U.S. Early Feasibility Study (EFS) at Cardiovascular Research Technologies (CRT 2026) and Sydney Valves 2026, supporting ongoing scientific engagement and exchange with the clinical community<\/li>\n<\/ul>\n<p>\u201cQ1 2026 reflects strong execution across the PARADIGM Trial, with patient enrollment ongoing in Europe and continued progress on key recruitment activities globally. With the U.S. now on line and first patients enrolled, we are firmly executing our strategy and building momentum toward the commercial launch of DurAVR<sup>\u00ae<\/sup>,\u201d said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris.<\/p>\n<p align=\"justify\">\n        <strong>Business &amp; Operations<\/strong>\n      <\/p>\n<p align=\"justify\">Following initiation of our global pivotal trial in Q4 2025, we are seeing continued progress across Europe, and the United States where patient enrollment has recently commenced.<\/p>\n<p align=\"justify\">Clinical centers are advancing through key start up milestones, including ethics and regulatory approvals, site initiation visits and investigator training, alongside active patient screening and enrollment at activated sites.<\/p>\n<p align=\"justify\">In the United States, recent coverage determination by the Centers for Medicare and Medicaid Services (CMS) is expected to facilitate patient recruitment by supporting reimbursement and facilitating site-level adoption. Eligible procedures performed at participating U.S. study sites are covered under the Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32.<\/p>\n<p align=\"justify\">Collectively, these activities are supporting growing enrollment momentum as additional sites come on line and contribute to trial execution.<\/p>\n<p align=\"justify\">\n        <strong>Financial Results<\/strong>\n      <\/p>\n<p align=\"justify\">The financial results for Anteris for the quarter ended March 31, 2026, are presented below. All amounts in $ refer to U.S. dollars.<\/p>\n<p align=\"justify\">The Company\u2019s net operating cash outflows for the three months ended March 31, 2026, were $28.7 million, attributable to clinical, regulatory and manufacturing requirements to support the PARADIGM Trial. This clinical focus is reflected in the Company\u2019s operating expenditures, with R&amp;D expenses of $17.5 million driven by the upscaling of manufacturing and quality capabilities, including process design and validation activities and the expansion of headcount, and activities linked to the PARADIGM Trial, including clinical costs associated with the enrollment of additional patients and the scaling of our field-based clinical team. These were partly offset by reduced DurAVR<sup>\u00ae<\/sup> THV product research costs.<\/p>\n<p align=\"justify\">Anteris refers to the detailed financial information contained in its Form 10-Q filing including the Management Discussion &amp; Analysis and the Risks.<\/p>\n<p align=\"justify\">\n        <strong>ENDS<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>About the PARADIGM Trial<\/strong>\n      <\/p>\n<p align=\"justify\">The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR<sup>\u00ae<\/sup> Transcatheter Heart Valve (\u201cTHV\u201d) compared to commercially available transcatheter aortic valve replacements (TAVRs).<\/p>\n<p align=\"justify\">This head-to-head study will enrol approximately 1,000 patients in the \u2018All Comers Randomized Cohort&#8217; with 1:1 randomization of patients who will receive either the DurAVR<sup>\u00ae<\/sup> THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure.<\/p>\n<p align=\"justify\">For further information, please refer to ClinicalTrials.gov NCT07194265.<\/p>\n<p align=\"justify\">\n        <strong>About Anteris<\/strong>\n      <\/p>\n<p align=\"justify\">Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.<\/p>\n<p align=\"justify\">Anteris\u2019 lead product, the DurAVR<sup>\u00ae<\/sup> THV, was designed in collaboration with the world\u2019s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis \u2013 a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR<sup>\u00ae<\/sup> THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR<sup>\u00ae <\/sup>THV is made using a single piece of molded ADAPT<sup>\u00ae<\/sup> tissue, Anteris\u2019 patented anti-calcification tissue technology. ADAPT<sup>\u00ae<\/sup> tissue, which is FDA-cleared, has been used clinically for over 10\u00a0years and distributed for use in over 55,000 patients worldwide. The DurAVR<sup>\u00ae<\/sup> THV System is comprised of the DurAVR<sup>\u00ae<\/sup> valve, the ADAPT<sup>\u00ae<\/sup> tissue, and the balloon-expandable ComASUR<sup>\u00ae<\/sup> Delivery System.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This announcement contains forward-looking statements, including statements regarding the expectation that achievement of CMS coverage will facilitate U.S. site activation, accelerating operational momentum across participating centers, and the PARADIGM Trial. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cbudget,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cstrategy,\u201d \u201cplan,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result\u201d and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under \u201cRisk Factors\u201d in Anteris\u2019 Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.<\/p>\n<p align=\"justify\">\n        <strong>For more information:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>Global Investor Relations<\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>Investor Relations (US)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:investors@anteristech.com\" rel=\"nofollow\" target=\"_blank\">investors@anteristech.com<\/a>\u00a0<\/td>\n<td>\n            <a href=\"mailto:mchatterjee@bplifescience.com\" rel=\"nofollow\" target=\"_blank\">mchatterjee@bplifescience.com<\/a>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Debbie Ormsby<\/td>\n<td>Malini Chatterjee, Ph.D.<\/td>\n<\/tr>\n<tr>\n<td>Anteris Technologies Global Corp.<\/td>\n<td>Blueprint Life Science Group<\/td>\n<\/tr>\n<tr>\n<td>+61 1300 550 310 | +61 7 3152 3200<\/td>\n<td>+1 917 330 4269<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:99%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%\">Website<\/td>\n<td style=\"max-width:85%;width:85%;min-width:85%\">\n            <a href=\"https:\/\/www.anteristech.com\" rel=\"nofollow\" target=\"_blank\">www.anteristech.com<\/a>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>X<\/td>\n<td>@AnterisTech<\/td>\n<\/tr>\n<tr>\n<td>LinkedIn<\/td>\n<td>\n            <a href=\"https:\/\/www.linkedin.com\/company\/anteristech\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.linkedin.com\/company\/anteristech<\/a>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2NmNTExYTktYzM0NC00OTE5LWI2MmEtYTdiYmRkYmY0ZGIzLTEyNzM3NjMtMjAyNi0wNS0xMi1lbg==\/tiny\/Anteris-Technologies-Pty-Ltd.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) &#8212; Anteris Technologies Global Corp. (\u201cAnteris\u201d or the \u201cCompany\u201d) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. Q1 2026 Highlights Completed aggregate capital raises totalling $320 million in January 2026 to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR\u00ae THV System Advanced PARADIGM Trial recruitment, supported by ongoing regulatory and operational work to activate additional countries and sites \u2013 post quarter-end, U.S. enrollment commenced Presented clinical data from the ongoing EMBARK Study &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Anteris Announces Results for the First Quarter of 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-961885","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anteris Announces Results for the First Quarter of 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anteris Announces Results for the First Quarter of 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) &#8212; Anteris Technologies Global Corp. (\u201cAnteris\u201d or the \u201cCompany\u201d) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. Q1 2026 Highlights Completed aggregate capital raises totalling $320 million in January 2026 to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR\u00ae THV System Advanced PARADIGM Trial recruitment, supported by ongoing regulatory and operational work to activate additional countries and sites \u2013 post quarter-end, U.S. enrollment commenced Presented clinical data from the ongoing EMBARK Study &hellip; Continue reading &quot;Anteris Announces Results for the First Quarter of 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T23:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anteris Announces Results for the First Quarter of 2026\",\"datePublished\":\"2026-05-12T23:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/\"},\"wordCount\":975,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/\",\"name\":\"Anteris Announces Results for the First Quarter of 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM=\",\"datePublished\":\"2026-05-12T23:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-results-for-the-first-quarter-of-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anteris Announces Results for the First Quarter of 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anteris Announces Results for the First Quarter of 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/","og_locale":"en_US","og_type":"article","og_title":"Anteris Announces Results for the First Quarter of 2026 - Market Newsdesk","og_description":"MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) &#8212; Anteris Technologies Global Corp. (\u201cAnteris\u201d or the \u201cCompany\u201d) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. Q1 2026 Highlights Completed aggregate capital raises totalling $320 million in January 2026 to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR\u00ae THV System Advanced PARADIGM Trial recruitment, supported by ongoing regulatory and operational work to activate additional countries and sites \u2013 post quarter-end, U.S. enrollment commenced Presented clinical data from the ongoing EMBARK Study &hellip; Continue reading \"Anteris Announces Results for the First Quarter of 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-12T23:03:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anteris Announces Results for the First Quarter of 2026","datePublished":"2026-05-12T23:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/"},"wordCount":975,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/","name":"Anteris Announces Results for the First Quarter of 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM=","datePublished":"2026-05-12T23:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTA0NiM3NTk3NDI3IzIyNjIyMTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-results-for-the-first-quarter-of-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anteris Announces Results for the First Quarter of 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=961885"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961885\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=961885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=961885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=961885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}